{"title":"Cholinergic Urticaria","description":"\u003cp data-mce-fragment=\"1\"\u003eCholinergic urticaria is a common form of inducible urticaria (hives) in which wheals and\/or angioedema are triggered by physical exertion, emotional stress, heat or sweating. The course of cholinergic urticaria is often chronic.\u003c\/p\u003e","products":[{"product_id":"choluas","title":"Cholinergic Urticaria Activity Score (CholUAS)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003cp\u003eThe CholUAS is a disease-specific questionnaire to assess the disease activity in patients with cholinergic urticaria. It consists of a daily three-item questionnaire plus one global question and is quick and easy to use for patients.\u003c\/p\u003e\n\u003cp\u003eThe CholUAS was developed at the Charité by a team headed by Sabine Altrichter, Karsten Weller and Marcus Maurer. The questions included in the CholUAS were created together with patients. The making of the CholUAS also involved impact and factor analyses as well as visual validity testing, and the development of a scoring system. The CholUAS is also suitable for the use in patient care as well as clinical research and studies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQuick Facts CholUAS:\u003c\/strong\u003e\u003cbr\u003eNumber of items: 3+1\u003cbr\u003eSuited for: All adult (\u003cspan data-mce-fragment=\"1\"\u003e≥\u003c\/span\u003e18 years old) patients with cholinergic urticaria\u003cbr\u003eAssessment: Prospectively, every day\u003cbr\u003eScoring: average weekly score calculation (scoring template available)\u003cbr\u003eCopyright: Moxie GmbH (www.moxie-gmbh.de)\u003cbr\u003eTerms of use: Free for routine clinical use and non-commercial research, small fee for use in clinical trials\/commercial research\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eReference\u003c\/strong\u003e:\u003cbr\u003eKoch K, Weller K, Werner A, Maurer M, Altrichter S. Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria. J Allergy Clin Immunol. 2016 Nov;138(5):1483-1485.e9. doi: 10.1016\/j.jaci.2016.05.026. \u003c\/p\u003e\n\u003cp\u003eSchnarkowski P, Salameh P, Grekowitz E., Terhorst E, Maurer M, Weller K, Altrichter S, Validation of the cholinergic urticaria activity score, CholUAS, submitted for publication 01\/2024\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cbr\u003e\u003c\/p\u003e","brand":"MOXIE","offers":[{"title":"Default Title","offer_id":47540196114770,"sku":"","price":0.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0791\/7351\/7650\/files\/CholinergicUrticariaActivityScore_CholUAS.png?v=1704970165"},{"product_id":"cholu-qol","title":"Cholinergic Urticaria Quality of Life Questionnaire (CholU-QoL)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003cp\u003eThe Quality of Life Questionnaire for Patients with Cholinergic Urticaria (CholU-QoL) is the first and only available quality of life questionnaire specifically designed for patients with cholinergic urticaria. CholU-QoL is easy to use and has been validated specifically for patients with cholinergic urticaria.\u003c\/p\u003e\n\u003cp\u003eThe CholU-QoL was developed at the Charité by a team headed by Dr. Sabine Altrichter, PD Dr. Karsten Weller and Prof. Marcus Maurer. Initially, 96 questions were created using established procedures and in accordance with international recommendations. Using impact and factor analyses as well as visual validity testing, 28 of these questions were selected for the final CholU-QoL instrument. This instrument was then checked for validity and reliability and examined with regard to possible influencing factors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQuick Facts CholU-QoL:\u003c\/strong\u003e\u003cbr\u003eNumber of items: 28\u003cbr\u003eRecall period: 2 weeks\u003cbr\u003eSuited for: All adult (≥18 years old) patients with cholinergic urticaria                                      \u003cbr\u003eCopyright: Moxie GmbH (www.moxie-gmbh.de)\u003cbr\u003eTerms of use: Free for routine clinical use and non-commercial research, small fee for use in clinical trials\/commercial research\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eReference\u003c\/strong\u003e:\u003cbr\u003eRuft J, Asady A, Staubach P, Casale T, Sussmann G, Zuberbier T, Maurer M, Weller K, Altrichter S. Development and validation of the Cholinergic Urticaria Quality-of-Life Questionnaire (CholU-QoL). Clin Exp Allergy. 2018 Apr;48(4):433-444. doi: 10.1111\/cea.13102. Epub 2018 Feb 28.\u003c\/p\u003e\n\u003cp\u003eAltrichter S, Mellerowicz E, Terhorst-Molawi D, Grekowitz E, Weller K, Maurer M. Disease Impact, Diagnostic Delay, and Unmet Medical Needs of Patients With Cholinergic Urticaria in German-Speaking Countries. Front Allergy. 2022 May 25;3:867227. doi: 10.3389\/falgy.2022.867227.\u003c\/p\u003e","brand":"MOXIE","offers":[{"title":"Default Title","offer_id":47408585998674,"sku":"","price":0.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0791\/7351\/7650\/files\/CholinergicUrticariaQualityofLifeQuestionnaire_CholU-QoL.png?v=1704970168"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0791\/7351\/7650\/collections\/Mockup_6db0bc65-529b-4659-bf7b-cf2763f73eb4.png?v=1706276388","url":"https:\/\/moxie-gmbh.de\/collections\/cholinergic-urticaria.oembed","provider":"MOXIE","version":"1.0","type":"link"}